Key Developments

On April 4, 2024, Glucotrack, Inc., a medical device company, and TTP plc, a technology company, announced the completion of computational modeling for Glucotrack’s implantable Continuous Blood Glucose Monitor (CBGM), suggesting sensor longevity beyond three years. Glucotrack has engaged TTP for the development of computational modeling, which addresses enzyme longevity for use in long-term implantable electrochemical sensors.
On March 5, 2024, Dexcom, Inc., a company that develops, manufactures, produces, and distributes continuous glucose monitoring systems for diabetes management, announced that it had received an approval from the U.S. Food and Drug Administration for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for anyone 18 years and older.
On February 6, 2024, Dexcom, Inc. launched Dexcom ONE+ in Spain, Belgium, and Poland. Dexcom ONE+ is a customizable continuous glucose monitoring solution that can be worn at three different locations on the body.
In November, 2023, Nemaura, a medical technology company, announced the expansion into the U.K. with its Metabolic Health Program. Under this initiative, the company has integrated continuous glucose monitoring (CGM) with its behavioral change program.
In May 2021, F. Hoffmann-La Roche Ltd., a healthcare company, and Ellerca Health Corp., a digital therapeutics company, announced that they had launched Accu-Chek + 360Care, combining F. Hoffmann-La Roche Ltd.’s Accu-Chek Guide blood glucose meter, customized home delivery of testing strips and Ellerca Health Corp’s self-management digital program, 360Care, which empowers patients to be in control of their own treatment schedule with access to a team of health coaches.